Skip to content

Tweetorial #3: Best Practices with T-cell Therapy
***Post-Survey & Application for CME Credit***

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.What are your credentials?(Required.)
2.What is your community of practice?
3.Based on an Association of Community Cancer Centers @ACCCBuzz survey conducted in 2020, which of the following challenges was most frequently cited as a barrier to treatment with bispecific antibodies?(Required.)
4.74-YOM dx w/ IgG MM w/ t(11;14) here discuss tx with a bispecific ab. After explaining tx is continued until disease progression, he asks if he needs to receive tx and monitoring at an academic center. Which of the following is the best response regarding where tx is delivered? (Required.)
5.The director of the cancer center is exploring providing bispecific antibodies or CAR-T for multiple myeloma. Which of the following processes would need to be developed in order to provide both CAR-T and bispecific antibodies? (Required.)
EVALUATION FORM
6.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
TRANSLATE strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM
7.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective.
The educational resources provided to me at the educational activity are useful to my practice.
8.Overall, was this activity fair, balanced and free from commercial bias? 
9.If no, please explain:
10.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
11.As a result of what I learned, I intend to make changes in my practice:
12.What change(s) will you incorporate into your practice as a result of what you have learned in this activity?
13.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
14.I certify that I have participated in the continuing education activity entitled, "Not Just Another Monoclonal Antibody: Best Practices for Providing T-cell Therapies" and claim 0.25 AMA PRA Category 1 CreditTM.(Required.)
15.If you are claiming credit, please provide your contact information so we can send your certificate. Certificates will be provided within 4-6 weeks.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice